Mark H. Rapaport, MD

Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, California

  • 12Articles
  • 32.4KReads
  • 2000–2026Active
  • 69Collaborators
  • 82Citations

About

Mark H. Rapaport, MD, is affiliated with the Department of Psychiatry and Behavioral Sciences at Stanford University. With publications spanning from 2000 to 2026, Rapaport has contributed extensively to the fields of depression, posttraumatic stress disorder, anxiety, panic disorder, and psychopharmacology. His work includes clinical trials and analyses of antidepressant treatments, evaluation of pharmacodynamic effects, and studies on quality of life in psychiatric conditions. Frequent collaborators include A. John Rush and Michael E. Thase.

Publications

JCP
When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?
ASCP Corner

When Do Physical Symptoms After Antidepressant Cessation Reflect Pharmacodynamic versus Non-pharmacodynamic Clinical Phenomena?

August 6, 2026

Focuses on descriptive symptom phenomenology and strategies to minimize discomfort during antidepressant cessation, with possible explanations for unusual, delayed, or protracted symptoms in patients for whom non-pharmacodynamic features may...
, , , et al
JCP
In Memoriam

Who Was Lori Altshuler?

March 23, 2016

Read about Lori Altshuler's life and how she effected psychiatry throughout her life.
JCP
Original Research

The Prevalence and Severity of Depressive Symptoms Along the Spectrum of Unipolar Depressive Disorders: A Post Hoc Analysis

November 15, 2013

, , , et al
JCP
Article

Teaching the Teacher: A Report From the Third Annual American Society of Clinical Psychopharmacology Teaching Session

March 15, 2013

, ,
JCP
Original Research

A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Trial of Ziprasidone as Monotherapy for Major Depressive Disorder

December 15, 2012

, , , et al
JCP
Article

New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting: A Great Opportunity for Early Career Psychiatrists

April 15, 2012

, , , et al
JCP
ASCP Corner

Omega-3 Fatty Acids and Depression: From Cellular Mechanisms to Clinical Care

February 15, 2011

,
JCP
Original Research

A Randomized, Double-Blind, Active-Control Study of Sertraline Versus Venlafaxine XR in Major Depressive Disorder

November 15, 2006

, , , et al
JCP
Original Research

Posttraumatic Stress Disorder and Quality of Life: Results Across 64 Weeks of Sertraline Treatment

January 1, 2002

, ,
JCP
Original Research

An Open-Label, 12-Week Clinical and Sleep EEG Study of Nefazodone in Chronic Combat-Related Posttraumatic Stress Disorder

October 1, 2001

, , , et al
JCP
Article

Prevalence, Recognition, and Treatment of Comorbid Depression and Anxiety

January 11, 2001

JCP
Original Research

Sertraline Treatment of Panic Disorder: Response in Patients at Risk for Poor Outcome

December 31, 2000

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe